Erasca Inc
NASDAQ:ERAS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its Industry Average (6.2), the stock would be worth $0 (100% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | $19.15 |
0%
|
| Industry Average | 6.2 | $0 |
-100%
|
| Country Average | 3 | $0 |
-100%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Erasca Inc
NASDAQ:ERAS
|
5.4B USD | 0 | -43.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 6.6 | 83.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 6.1 | 23.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 5.8 | 18.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 8.4 | 27.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 4 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 10.7 | 37.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 3.5 | 31.1 |
Market Distribution
Other Multiples
Erasca Inc
Glance View
Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The company is headquartered in San Diego, California and currently employs 123 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm is engaged in oncology and RAS targeting to create therapies and combination regimens for the treatment of cancer. Its product candidates are ERAS-007 and ERAS-601, which together comprises its MAPKlamp. In addition, it also includes two discovery programs, ERAS-9 and ERAS-11, small molecule inhibitor programs targeting SOS1 and MYC, respectively. Its MAPKlamp is an approach targeting upstream and downstream nodes in the RAS/MAPK pathway designed to shut down, or clamp, the signaling of various oncogenic drivers, such as RTKs, NF1, RAS, RAF, and MEK alterations trapped in between any nodes involving this pathway. With its MAPKlamp approach, it induces tumor regression in RAS/MAPK pathway-driven cancers, while also blocking the escape routes that lead to tumor resistance.
